Fuji Pharma Co. Ltd. Stock
€9.15
Your prediction
Fuji Pharma Co. Ltd. Stock
Pros and Cons of Fuji Pharma Co. Ltd. in the next few years
Pros
Cons
Performance of Fuji Pharma Co. Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Fuji Pharma Co. Ltd. | -2.140% | 0.538% | -4.592% | 12.651% | -15.766% | 1.081% | -29.773% |
| Hisamitsu Pharmaceutical | -1.820% | 0.000% | -6.780% | -9.091% | -17.910% | -54.918% | -41.050% |
| Mochida Pharmaceutical Co. Ltd. | -2.140% | 1.081% | -3.109% | -17.982% | -9.223% | -37.667% | -53.747% |
| Sosei Group Corp | -0.570% | -1.667% | -6.349% | -50.559% | -0.562% | -34.926% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Certain aspects of Fuji Pharma's financials provoke optimism, while others necessitate caution. Thus, it is of significant importance to carry out a thorough analysis of its financials to get a better understanding of the company's performance, prospects, and potential risks.
Pros: * *Profitability:** One standout aspect of Fuji Pharma's financials is its robust profit margins. With an 8.4% profit margin and an operating margin of 12.76%, the company portrays strong profitability, indicating effective cost control and strong pricing power. These numbers are generally superior compared to many players within the same industry.
Robust Revenue Generation: The firm's revenue has been consistently escalating, emphasizing the successful implementation of their strategies. The firm's total revenue as of the trailing twelve months is approximately 40.89 billion EUR.